Volume 6, Issue 22 (6-1997)                   JGUMS 1997, 6(22): 53-62 | Back to browse issues page

XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Kosha .. FUTURE OF ASTHMA DRUG THERAPY. JGUMS 1997; 6 (22) :53-62
URL: http://journal.gums.ac.ir/article-1-1919-en.html
Abstract:   (1680 Views)
ABSTRACT:
Asthma is a chronic disease in which hyperactivity of airways to different stimuli is responsible for pathophysiologic changes seen. With respect to the pathophysiologic changes seen the treatment can be divided into two groups: bronchodilator and anti-inflammatory drugs.
Bronchodilators consist of beta 2 agonists (salbutmol), Xanthine (theophilline) and anticholinergic(ipratropium).Anti -inflammatory drugs used in the form of cromoglycate -NA(for prophylaxis )and corticosteroids (prednison)for treatment of asthma.
Corticosteroids have good effects in the treatment of both acute attacks and in chronic asthma; and in severe cases of asthma, they are the last drugs which can be effective but because of their systemic effect, it seems better to substitute them with the new antiinflammantory drugs .
First of all, it is necessary to discuss about the pathophysiology of asthma briefly, and then a little about leukotrienes antagonists and phosphodiestrase inhibitors and the other new drugs under investigation.
 
Full-Text [PDF 38812 kb]   (790 Downloads)    
Review Paper: Research | Subject: Special
Received: 2019/03/12 | Accepted: 2019/03/12 | Published: 2019/03/12

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Journal of Guilan University of Medical Sciences

Designed & Developed by : Yektaweb